William McBride, MD
Family Medicine · Alexandria, LANPI 1497893325
Payments from drug & device makers
Across 167 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$512
- Novo Nordisk$377
- Lilly USA, LLC$267
- GSK$222
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$183
- AbbVie$123
- plus $979 from 27 others
What the payments were for
- Food & beverage$2,652100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $512 |
| Novo Nordisk | 27 | $377 |
| Lilly USA, LLC | 16 | $267 |
| GSK | 13 | $222 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $183 |
| AbbVie | 7 | $123 |
| Amgen | 6 | $120 |
| Pfizer | 7 | $118 |
| Abbott | 6 | $86 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| Boehringer Ingelheim | 3 | $52 |
| Eisai Inc. | 3 | $41 |
| Bayer | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Corcept Therapeutics | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Novartis | 2 | $28 |
| Averitas Pharma Inc. | 1 | $22 |
| Exact Sciences | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| Medtronic | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,664 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 165 | $172,415 |
| MounjaroTirzepatide | 96 | $119,607 |
| JardianceEmpagliflozin | 76 | $86,974 |
| FarxigaDapagliflozin Propanediol | 81 | $76,589 |
| JanuviaSitagliptin Phosphate | 65 | $58,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $55,862 |
| XareltoRivaroxaban | 49 | $50,918 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $39,747 |
| OzempicSemaglutide | 30 | $37,942 |
| EntrestoSacubitril/Valsartan | 28 | $32,349 |
| TrulicityDulaglutide | 28 | $30,824 |
| Praluent PenAlirocumab | 19 | $26,284 |
| LinzessLinaclotide | 27 | $23,129 |
| NamzaricMemantine Hcl/Donepezil Hcl | 15 | $14,377 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $13,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $118 | $177,389180 claims |
| Lilly USA, LLCMounjaro, Trulicity | $267 | $150,431124 claims |
| Boehringer IngelheimJardiance | $52 | $86,97476 claims |
| AstraZenecaFarxiga | $512 | $76,58981 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $222 | $61,68164 claims |
| Johnson & JohnsonXarelto | $29 | $50,91849 claims |
| AbbVieLinzess, Namzaric, Synthroid | $123 | $39,983105 claims |
| Novo NordiskOzempic | $377 | $37,94230 claims |
| NovartisEntresto | $28 | $32,34928 claims |
| Sanofi-aventis U.S. LLCLantus | $81 | $2,52017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Alexandria
- Michael ScrepetisAlexandria$27K
- Gregory BevelsAlexandria$24K
- Kenneth BrownAlexandria$17K
- Gregory BrianAlexandria$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.